Corient Private Wealth LP Buys New Position in Celcuity, Inc. $CELC

Corient Private Wealth LP bought a new stake in Celcuity, Inc. (NASDAQ:CELC) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,015 shares of the company’s stock, valued at approximately $1,257,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of CELC. PNC Financial Services Group Inc. increased its position in Celcuity by 20.1% in the 1st quarter. PNC Financial Services Group Inc. now owns 514 shares of the company’s stock valued at $59,000 after acquiring an additional 86 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Celcuity by 15.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 944 shares of the company’s stock valued at $99,000 after purchasing an additional 124 shares during the last quarter. US Bancorp DE grew its stake in shares of Celcuity by 25.4% in the 3rd quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after purchasing an additional 143 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Celcuity by 1.4% during the fourth quarter. Intech Investment Management LLC now owns 12,983 shares of the company’s stock worth $1,295,000 after purchasing an additional 183 shares during the period. Finally, Aristides Capital LLC lifted its holdings in shares of Celcuity by 2.0% during the fourth quarter. Aristides Capital LLC now owns 15,303 shares of the company’s stock worth $1,526,000 after purchasing an additional 303 shares during the period. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Needham & Company LLC reduced their price objective on shares of Celcuity from $157.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, August 14th. HC Wainwright reissued a “buy” rating and issued a $155.00 price target on shares of Celcuity in a report on Friday, August 14th. Wall Street Zen downgraded Celcuity from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Leerink Partners set a $155.00 price objective on Celcuity in a research report on Tuesday, June 2nd. Finally, Stifel Nicolaus reduced their target price on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a report on Friday, August 14th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Celcuity currently has a consensus rating of “Moderate Buy” and a consensus price target of $154.55.

Celcuity Price Performance

Celcuity stock opened at $95.70 on Friday. The stock has a market capitalization of $4.68 billion, a P/E ratio of -22.26 and a beta of 0.19. Celcuity, Inc. has a 12-month low of $44.42 and a 12-month high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The firm’s 50-day moving average is $94.58 and its two-hundred day moving average is $106.76.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). Equities analysts predict that Celcuity, Inc. will post -4.75 earnings per share for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.